Radical prostatectomy for clinical stage T3a disease

BACKGROUND Men with clinical stage T3a disease are at high risk and are often encouraged to undergo radiation therapy with concomitant hormonal therapy. The long‐term outcomes among men treated with radical prostatectomy for clinical stage T3a disease were examined. METHODS Among 3397 men treated by...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 2007-04, Vol.109 (7), p.1273-1278
Main Authors: Freedland, Stephen J., Partin, Alan W., Humphreys, Elizabeth B., Mangold, Leslie A., Walsh, Patrick C.
Format: Article
Language:English
Subjects:
Adenocarcinoma - blood
Adenocarcinoma - pathology
Adenocarcinoma - surgery
Biological and medical sciences
Biopsy
Disease Progression
Disease-Free Survival
Follow-Up Studies
Humans
Lymphatic Metastasis - diagnosis
Male
Medical sciences
Middle Aged
Neoplasm Staging
Nephrology. Urinary tract diseases
prostate cancer
Prostate-Specific Antigen - blood
Prostatectomy
Prostatic Neoplasms - blood
Prostatic Neoplasms - pathology
Prostatic Neoplasms - surgery
PSA
radical prostatectomy
Risk Factors
TNM
Tumors
Tumors of the urinary system
Urinary tract. Prostate gland
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND Men with clinical stage T3a disease are at high risk and are often encouraged to undergo radiation therapy with concomitant hormonal therapy. The long‐term outcomes among men treated with radical prostatectomy for clinical stage T3a disease were examined. METHODS Among 3397 men treated by radical prostatectomy by 1 surgeon between 1987 and 2003, 62 (1.8%) men were identified who had clinical stage T3a disease. Among the 56 men not treated with neoadjuvant or adjuvant therapies before prostate‐specific antigen (PSA) recurrence, the long‐term outcomes of PSA‐free survival, metastasis‐free survival, and prostate cancer specific survival were examined. Median and mean follow‐up after surgery were 10.3 and 13 years, respectively (range, 1–17). RESULTS Ninety‐one percent of men in this group had pathological T3 disease. PSA‐free survival at 15 years after surgery was 49%. Metastasis‐free survival and cause‐specific survival at 15 years after surgery were 73% and 84%, respectively. Among men with a PSA recurrence, 46% received secondary therapy before metastasis. The only preoperative or pathological feature that predicted risk of prostate cancer death was lymph node metastasis (hazard ratio [HR]: 9.22, 95% confidence interval [CI]: 1.06–80.02, P = .044). Among the 28 men with a PSA recurrence, PSA doubling time (PSADT) data were available for 23, of which 11 (48%) has a PSADT ≥9 months. No patient with a PSADT ≥9 months died of prostate cancer. A PSADT
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.22544